



## Ind-Swift LABORATORIES LIMITED

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, 5061850, 5061853  
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com  
CIN No. L24232CH1995PLC015553



Ref: ISLL:CH:2025

Date: 4<sup>th</sup> August, 2025

**The President  
Corporate Relationship Department  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai 400 001**

**The Vice President,  
Listing Compliance Department,  
National Stock Exchange of India Limited,  
Exchange Plaza, 5<sup>th</sup> Floor  
Plot No. C/2, G-Block,  
Bandra Kurla Complex, Bandra (E),  
Mumbai 400 051**

**BSE Scrip Code: 532305**

**NSE Symbol: INDSWFTLAB**

**SUB: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Ma'am,

We have received attached intimation under Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 on 4<sup>th</sup> August, 2025 from M/s. Essix Biosciences Limited, regarding acquisition of 11,00,000 equity shares upon conversion of equivalent numbers of warrants into equity.

We request you to treat this intimation as compliance with the aforesaid regulations and take the same on record.

For IND-SWIFT LABORATORIES LTD.



**PARDEEP VERMA  
VP-CORPORATE AFFAIRS &  
COMPANY SECRETARY**

Encl: a/a

# Essix Biosciences Limited

Regd. Off. : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh - 160101 (INDIA)  
Phone : +91-172-2730503, 2730920, Fax : +91-172-2730504, 2736294  
Factory : Plot No. B-4 & 5, Industrial Focal Point, Derabassi, Punjab (India)  
Ph. 01762-281278, 79. CIN NO. U74999CH1993PLC033428

---

Date: August 04, 2025

To,  
Company Secretary & Compliance Officer  
Ind- Swift Laboratories Limited  
SCO:850, Shivalik Enclave, NAC,  
Manimajra, Chandigarh -160101, India

**Subject: Submission of disclosure under Regulation 7(2)(a) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.**

Dear Sir/Madam,

With reference to the above-captioned subject, please note that I, Himanshu Jain, on behalf of Essix Biosciences Limited ('Essix'), Promoter of Ind- Swift Laboratories Limited ('the Company') do hereby submit that Essix has acquired 11,00,000 Equity Shares pursuant to the conversion of fully convertible warrants of the Company having face value of Rs. 10/- each representing 1.50% of the post allotment paid-up equity share capital of the Company on August 01, 2025, on a preferential basis.

In reference to the above, kindly find enclosed herewith the disclosure required under Regulation 7(2)(a) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

Kindly take the above information on your records.

For Essix Biosciences Limited

  
  
Himanshu Jain  
Director  
DIN: 00014533